Best Menopause & Cardiovascular Disease Papers (2024–2026)
1. Management of Menopause for Women with Cardiovascular Disease (BMS, 2024)
Why important:
Helped clinicians safely prescribe HRT in women with controlled cardiovascular risk
Encouraged individualized rather than fear-based prescribing
Clinical impact:
This directly changed menopause clinic practice.
2. Menopause and Risk of Atherosclerotic Cardiovascular Disease (2025)
Why important:
Strengthened evidence that menopause itself contributes to ASCVD risk beyond aging alone
Clinical impact:
Supports earlier lipid and vascular screening in midlife women.
3. Cardiovascular Disease Risk in Women with Menopause (2025)
Why important:
Integrated lifestyle, inflammatory, metabolic, and vascular mechanisms
Clinical impact:
Promoted menopause as a preventive cardiology opportunity.
4. Menopause Potentially Linked to Adverse Cardiovascular Health Through Blood Fat Changes (2024)
Why important:
Demonstrated rapid lipid-profile deterioration around menopause
Clinical impact:
Increased calls for earlier ApoB/lipid screening and metabolic monitoring
5. Premature Menopause and Lifetime Coronary Heart Disease Risk (2026)
Why important:
Showed menopause before 40 substantially raises lifetime CHD risk
Clinical impact:
Reinforced premature menopause as a major cardiovascular risk factor.
6. Dynamics of Menopause from Deconvolution of Millions of Lab Tests (2025)
Why it changed practice:
Demonstrated menopause-related physiologic changes across multiple organ systems
Showed changes begin many years before final menstrual period
Why it's important:
This systems-biology approach may eventually redefine diagnostic biomarkers and earlier intervention.
Why these cardiovascular papers matter so much
Menopause is now viewed as a cardiometabolic transition
The field has shifted from:
“menopause causes symptoms” to: “menopause alters long-term vascular biology.”
That is a profound conceptual change.
Cardiovascular disease kills more women than breast cancer
These studies emphasize that menopause care is preventive medicine—not merely symptom management.
HRT debates are becoming more nuanced
The newer evidence suggests:
timing matters
route matters
patient selection matters
transdermal estrogen may reduce thrombotic risk
This has transformed clinical prescribing.
Menopause is becoming integrated into preventive medicine
These papers are driving:
menopause cardiology clinics
earlier lipid screening
cognitive-risk assessment
individualized risk calculators
multidisciplinary menopause care
The field is shifting toward precision menopause medicine
Future menopause care is increasingly likely to incorporate:
genomics
neuroimaging
metabolomics
AI-driven risk prediction
personalized hormone strategies
Cardiovascular disease is now recognized as one of the most important menopause-related health domains because CVD remains the leading cause of death in women.
© 2026 Natural Equilibrium CIC
Natural Equilibrium CIC is a company registered in England and Wales.
Company number:17040985
Get in touch with us
